Introduction

MVC partners with WHO/ UCAB to develop high-quality and affordable biosimilar Palivizumab, the only measures to prevent respiratory syncytial virus (RSV) infection currently. 

RSV is the most common cause of lower respiratory tract infection (LRTI) in children younger than 2 years of age, among 1/3 cases are infants below six months of age. The RSV infections tend to be severe in high-risk patients such as patients with prematurity, congenital heart diseases, neuromuscular diseases and immune deficiencies.


Features

|Anti-RSV Biosimilars Development|

  1. UCAB leads the development of this project and oversees all phases of the development of biosimilar products, from the development of high-yield cell lines and production process development to coordinating the preclinical and clinical development program.
  2. The program hopes to provide affordable biosimilars to patients worldwide and to facilitate equal access, and equitable distribution.

Progress

  • UCAB has started the 'Controlled Human Infection Model' studies (CHIMs).

Anti-RSV Biosimilars

R&D/Preclinical Phase I Phase II Phase III Marketed


We use cookies to improve your user experience and for web traffic statistics purposes. By continuing to use this website, you agree to our use of cookies. Our Privacy & Cookie Policy contains more information on such use and explains how to disable cookies.
Agree